ID   PDE10_HUMAN             Reviewed;         779 AA.
AC   Q9Y233; Q6FHX1; Q9HCP9; Q9NTV4; Q9ULW9; Q9Y5T1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   15-MAR-2017, entry version 167.
DE   RecName: Full=cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A;
DE            EC=3.1.4.17;
DE            EC=3.1.4.35;
GN   Name=PDE10A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PDE10A2), AND PHOSPHORYLATION AT
RP   THR-16 (ISOFORM PDE10A2) BY PKA.
RC   TISSUE=Fetal lung;
RX   PubMed=10441464; DOI=10.1006/bbrc.1999.1013;
RA   Kotera J., Fujishige K., Yuasa K., Omori K.;
RT   "Characterization and phosphorylation of PDE10A2, a novel alternative
RT   splice variant of human phosphodiesterase that hydrolyzes cAMP and
RT   cGMP.";
RL   Biochem. Biophys. Res. Commun. 261:551-557(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM PDE10A1).
RC   TISSUE=Fetal lung;
RX   PubMed=10373451; DOI=10.1074/jbc.274.26.18438;
RA   Fujishige K., Kotera J., Michibata H., Yuasa K., Takebayashi S.,
RA   Okumura K., Omori K.;
RT   "Cloning and characterization of a novel human phosphodiesterase that
RT   hydrolyzes both cAMP and cGMP (PDE10A).";
RL   J. Biol. Chem. 274:18438-18445(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS PDE10A1 AND PDE10A2).
RC   TISSUE=Fetal brain;
RX   PubMed=10393245; DOI=10.1016/S0378-1119(99)00171-7;
RA   Loughney K., Snyder P.B., Uher L., Rosman G.J., Ferguson K.,
RA   Florio V.A.;
RT   "Isolation and characterization of PDE10A, a novel human 3',5'-cyclic
RT   nucleotide phosphodiesterase.";
RL   Gene 234:109-117(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PDE10A1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E.,
RA   Gilbert J.G.R., Clamp M.E., Bethel G., Milne S., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Andrews T.D., Ashwell R.I.S.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Banerjee R., Barker D.J.,
RA   Barlow K.F., Bates K., Beare D.M., Beasley H., Beasley O., Bird C.P.,
RA   Blakey S.E., Bray-Allen S., Brook J., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E.,
RA   Ellington A.E., Evans K.A., Faulkner L., Francis M.D., Frankish A.,
RA   Frankland J., French L., Garner P., Garnett J., Ghori M.J.,
RA   Gilby L.M., Gillson C.J., Glithero R.J., Grafham D.V., Grant M.,
RA   Gribble S., Griffiths C., Griffiths M.N.D., Hall R., Halls K.S.,
RA   Hammond S., Harley J.L., Hart E.A., Heath P.D., Heathcott R.,
RA   Holmes S.J., Howden P.J., Howe K.L., Howell G.R., Huckle E.,
RA   Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M., Joy A.A.,
RA   Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R., Lloyd D.M.,
RA   Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K.,
RA   McMurray A., Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T.,
RA   Novik K.L., Oliver K., Overton-Larty E.K., Parker A., Patel R.,
RA   Pearce A.V., Peck A.I., Phillimore B.J.C.T., Phillips S., Plumb R.W.,
RA   Porter K.M., Ramsey Y., Ranby S.A., Rice C.M., Ross M.T., Searle S.M.,
RA   Sehra H.K., Sheridan E., Skuce C.D., Smith S., Smith M., Spraggon L.,
RA   Squares S.L., Steward C.A., Sycamore N., Tamlyn-Hall G., Tester J.,
RA   Theaker A.J., Thomas D.W., Thorpe A., Tracey A., Tromans A., Tubby B.,
RA   Wall M., Wallis J.M., West A.P., White S.S., Whitehead S.L.,
RA   Whittaker H., Wild A., Willey D.J., Wilmer T.E., Wood J.M., Wray P.W.,
RA   Wyatt J.C., Young L., Younger R.M., Bentley D.R., Coulson A.,
RA   Durbin R.M., Hubbard T., Sulston J.E., Dunham I., Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM PDE10A1).
RC   TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 66-779, AND ALTERNATIVE SPLICING.
RX   PubMed=10998054; DOI=10.1046/j.1432-1327.2000.01661.x;
RA   Fujishige K., Kotera J., Yuasa K., Omori K.;
RT   "The human phosphodiesterase PDE10A gene genomic organization and
RT   evolutionary relatedness with other PDEs containing GAF domains.";
RL   Eur. J. Biochem. 267:5943-5951(2000).
RN   [8]
RP   DOMAIN, AND ENZYME REGULATION.
RX   PubMed=16330539; DOI=10.1074/jbc.M511468200;
RA   Gross-Langenhoff M., Hofbauer K., Weber J., Schultz A., Schultz J.E.;
RT   "cAMP is a ligand for the tandem GAF domain of human phosphodiesterase
RT   10 and cGMP for the tandem GAF domain of phosphodiesterase 11.";
RL   J. Biol. Chem. 281:2841-2846(2006).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [11]
RP   INVOLVEMENT IN IOLOD, VARIANTS IOLOD CYS-97 AND PRO-106, AND
RP   CHARACTERIZATION OF VARIANTS IOLOD CYS-97 AND PRO-106.
RX   PubMed=27058446; DOI=10.1016/j.ajhg.2016.03.015;
RA   Diggle C.P., Sukoff Rizzo S.J., Popiolek M., Hinttala R.,
RA   Schuelke J.P., Kurian M.A., Carr I.M., Markham A.F., Bonthron D.T.,
RA   Watson C., Sharif S.M., Reinhart V., James L.C., Vanase-Frawley M.A.,
RA   Charych E., Allen M., Harms J., Schmidt C.J., Ng J., Pysden K.,
RA   Strick C., Vieira P., Mankinen K., Kokkonen H., Kallioinen M.,
RA   Sormunen R., Rinne J.O., Johansson J., Alakurtti K., Huilaja L.,
RA   Hurskainen T., Tasanen K., Anttila E., Marques T.R., Howes O.,
RA   Politis M., Fahiminiya S., Nguyen K.Q., Majewski J., Uusimaa J.,
RA   Sheridan E., Brandon N.J.;
RT   "Biallelic mutations in PDE10A Lead to loss of striatal PDE10A and a
RT   hyperkinetic movement disorder with onset in infancy.";
RL   Am. J. Hum. Genet. 98:735-743(2016).
RN   [12]
RP   TISSUE SPECIFICITY, INVOLVEMENT IN ADSD2, VARIANTS ADSD2 LEU-290 AND
RP   LEU-324, AND CHARACTERIZATION OF VARIANTS ADSD2 LEU-290 AND LEU-324.
RX   PubMed=27058447; DOI=10.1016/j.ajhg.2016.02.015;
RA   Mencacci N.E., Kamsteeg E.J., Nakashima K., R'Bibo L., Lynch D.S.,
RA   Balint B., Willemsen M.A., Adams M.E., Wiethoff S., Suzuki K.,
RA   Davies C.H., Ng J., Meyer E., Veneziano L., Giunti P., Hughes D.,
RA   Raymond F.L., Carecchio M., Zorzi G., Nardocci N., Barzaghi C.,
RA   Garavaglia B., Salpietro V., Hardy J., Pittman A.M., Houlden H.,
RA   Kurian M.A., Kimura H., Vissers L.E., Wood N.W., Bhatia K.P.;
RT   "De novo mutations in PDE10A cause childhood-onset chorea with
RT   bilateral striatal lesions.";
RL   Am. J. Hum. Genet. 98:763-771(2016).
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.45 ANGSTROMS) OF 436-766 IN COMPLEXES WITH
RP   AMP; CAMP; GMP; CGMP AND MAGNESIUM, MUTAGENESIS OF ASP-554, FUNCTION,
RP   COFACTOR, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=17389385; DOI=10.1073/pnas.0700279104;
RA   Wang H., Liu Y., Hou J., Zheng M., Robinson H., Ke H.;
RT   "Structural insight into substrate specificity of phosphodiesterase
RT   10.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:5782-5787(2007).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 242-427 IN COMPLEX WITH CAMP,
RP   DOMAIN, AND SUBUNIT.
RX   PubMed=18477562; DOI=10.1074/jbc.M800595200;
RA   Handa N., Mizohata E., Kishishita S., Toyama M., Morita S.,
RA   Uchikubo-Kamo T., Akasaka R., Omori K., Kotera J., Terada T.,
RA   Shirouzu M., Yokoyama S.;
RT   "Crystal structure of the GAF-B domain from human phosphodiesterase
RT   10A complexed with its ligand, cAMP.";
RL   J. Biol. Chem. 283:19657-19664(2008).
CC   -!- FUNCTION: Plays a role in signal transduction by regulating the
CC       intracellular concentration of cyclic nucleotides. Can hydrolyze
CC       both cAMP and cGMP, but has higher affinity for cAMP and is more
CC       efficient with cAMP as substrate. May play a critical role in
CC       regulating cAMP and cGMP levels in the striatum, a region of the
CC       brain that contributes to the control of movement and cognition.
CC       {ECO:0000250|UniProtKB:Q8CA95, ECO:0000269|PubMed:17389385}.
CC   -!- CATALYTIC ACTIVITY: Nucleoside 3',5'-cyclic phosphate + H(2)O =
CC       nucleoside 5'-phosphate.
CC   -!- CATALYTIC ACTIVITY: Guanosine 3',5'-cyclic phosphate + H(2)O =
CC       guanosine 5'-phosphate.
CC   -!- COFACTOR:
CC       Name=a divalent metal cation; Xref=ChEBI:CHEBI:60240;
CC         Evidence={ECO:0000269|PubMed:17389385};
CC       Note=Binds 2 divalent metal cations per subunit. Site 1 may
CC       preferentially bind zinc ions, while site 2 has a preference for
CC       magnesium and/or manganese ions. {ECO:0000269|PubMed:17389385};
CC   -!- ENZYME REGULATION: Inhibited by dipyridamole and moderately by
CC       IBMX. cAMP acts as an allosteric activator.
CC       {ECO:0000269|PubMed:16330539}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=56 nM for cAMP {ECO:0000269|PubMed:17389385};
CC         KM=4.4 uM for cGMP {ECO:0000269|PubMed:17389385};
CC         Vmax=507 nmol/min/mg enzyme for cAMP
CC         {ECO:0000269|PubMed:17389385};
CC         Vmax=1860 nmol/min/mg enzyme for cGMP
CC         {ECO:0000269|PubMed:17389385};
CC   -!- PATHWAY: Purine metabolism; 3',5'-cyclic AMP degradation; AMP from
CC       3',5'-cyclic AMP: step 1/1.
CC   -!- PATHWAY: Purine metabolism; 3',5'-cyclic GMP degradation; GMP from
CC       3',5'-cyclic GMP: step 1/1.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:18477562}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Note=Located mostly to soluble
CC       cellular fractions.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Isoforms differ in their N-terminal region.;
CC       Name=PDE10A1;
CC         IsoId=Q9Y233-1; Sequence=Displayed;
CC       Name=PDE10A2;
CC         IsoId=Q9Y233-2; Sequence=VSP_004601;
CC         Note=Contains a phosphothreonine at position 16.
CC         {ECO:0000269|PubMed:10441464};
CC   -!- TISSUE SPECIFICITY: Abundant in the putamen and caudate nucleus
CC       regions of brain and testis, moderately expressed in the thyroid
CC       gland, pituitary gland, thalamus and cerebellum.
CC       {ECO:0000269|PubMed:10373451, ECO:0000269|PubMed:27058447}.
CC   -!- DOMAIN: The tandem GAF domains bind cAMP, and regulate enzyme
CC       activity. The binding of cAMP stimulates enzyme activity.
CC   -!- DOMAIN: Composed of a C-terminal catalytic domain containing two
CC       divalent metal sites and an N-terminal regulatory domain which
CC       contains one cyclic nucleotide-binding region.
CC   -!- PTM: Isoform PDE10A2: Phosphorylated on Thr-16.
CC       {ECO:0000269|PubMed:10441464}.
CC   -!- DISEASE: Dyskinesia, limb and orofacial, infantile-onset (IOLOD)
CC       [MIM:616921]: An autosomal recessive, early-onset hyperkinetic
CC       movement disorder characterized by axial hypotonia, dyskinesia of
CC       the limbs and trunk, orofacial dyskinesia, drooling, and
CC       dysarthria. The severity of the hyperkinesis is variable.
CC       {ECO:0000269|PubMed:27058446}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Striatal degeneration, autosomal dominant 2 (ADSD2)
CC       [MIM:616922]: An autosomal dominant disorder characterized by
CC       striatal degeneration and dysfunction of basal ganglia, resulting
CC       in hyperkinesis. {ECO:0000269|PubMed:27058447}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the cyclic nucleotide phosphodiesterase
CC       family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD32596.1; Type=Erroneous initiation; Note=Translation N-terminally shortened.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AB026816; BAA84467.1; -; mRNA.
DR   EMBL; AB020593; BAA78034.1; -; mRNA.
DR   EMBL; AF127479; AAD32595.1; -; mRNA.
DR   EMBL; AF127480; AAD32596.1; ALT_INIT; mRNA.
DR   EMBL; CR536567; CAG38804.1; -; mRNA.
DR   EMBL; AL117345; CAB92797.2; -; Genomic_DNA.
DR   EMBL; AL136130; CAB92797.2; JOINED; Genomic_DNA.
DR   EMBL; AL160160; CAB92797.2; JOINED; Genomic_DNA.
DR   EMBL; AL136130; CAI20436.1; -; Genomic_DNA.
DR   EMBL; AL117345; CAI20436.1; JOINED; Genomic_DNA.
DR   EMBL; AL160160; CAI20436.1; JOINED; Genomic_DNA.
DR   EMBL; AL160160; CAH72023.1; -; Genomic_DNA.
DR   EMBL; AL117345; CAH72023.1; JOINED; Genomic_DNA.
DR   EMBL; AL136130; CAH72023.1; JOINED; Genomic_DNA.
DR   EMBL; BC104858; AAI04859.1; -; mRNA.
DR   EMBL; BC104860; AAI04861.1; -; mRNA.
DR   EMBL; AB041798; BAB16383.1; -; Genomic_DNA.
DR   CCDS; CCDS47513.1; -. [Q9Y233-2]
DR   CCDS; CCDS5289.1; -. [Q9Y233-1]
DR   RefSeq; NP_001124162.1; NM_001130690.2. [Q9Y233-2]
DR   RefSeq; NP_006652.1; NM_006661.3. [Q9Y233-1]
DR   RefSeq; XP_011533690.1; XM_011535388.2. [Q9Y233-1]
DR   UniGene; Hs.348762; -.
DR   PDB; 1LRB; Model; -; A=501-757.
DR   PDB; 2OUN; X-ray; 1.56 A; A/B=439-766.
DR   PDB; 2OUP; X-ray; 1.56 A; A/B=439-766.
DR   PDB; 2OUQ; X-ray; 1.90 A; A/B=439-766.
DR   PDB; 2OUR; X-ray; 1.45 A; A/B=439-766.
DR   PDB; 2OUS; X-ray; 1.45 A; A/B=439-766.
DR   PDB; 2OUU; X-ray; 1.52 A; A/B=439-766.
DR   PDB; 2OUV; X-ray; 1.56 A; A/B=439-766.
DR   PDB; 2OUY; X-ray; 1.90 A; A/B=439-766.
DR   PDB; 2WEY; X-ray; 2.80 A; A/B=439-779.
DR   PDB; 2Y0J; X-ray; 2.43 A; A/B=432-764.
DR   PDB; 2ZMF; X-ray; 2.10 A; A/B=246-427.
DR   PDB; 3SN7; X-ray; 1.82 A; A/B=439-779.
DR   PDB; 3SNI; X-ray; 1.90 A; A/B=439-779.
DR   PDB; 3SNL; X-ray; 2.40 A; A/B=439-779.
DR   PDB; 3UI7; X-ray; 2.28 A; A/B=432-760.
DR   PDB; 3UUO; X-ray; 2.11 A; A/B=432-760.
DR   PDB; 3WI2; X-ray; 2.26 A; A/B=439-779.
DR   PDB; 3WS8; X-ray; 2.60 A; A/B=439-779.
DR   PDB; 3WS9; X-ray; 2.99 A; A/B=439-779.
DR   PDB; 3WYK; X-ray; 2.50 A; A/B=442-779.
DR   PDB; 3WYL; X-ray; 2.68 A; A/B=442-779.
DR   PDB; 3WYM; X-ray; 2.00 A; A/B=442-779.
DR   PDB; 4AEL; X-ray; 2.20 A; A/B=439-779.
DR   PDB; 4AJD; X-ray; 2.30 A; A/D=439-764.
DR   PDB; 4AJF; X-ray; 1.90 A; A/D=439-764.
DR   PDB; 4AJG; X-ray; 2.30 A; A/D=439-764.
DR   PDB; 4AJM; X-ray; 2.40 A; A/D=439-764.
DR   PDB; 4BBX; X-ray; 2.50 A; A/B=443-769.
DR   PDB; 4DDL; X-ray; 2.07 A; A/B=442-779.
DR   PDB; 4DFF; X-ray; 2.11 A; A/B=432-779.
DR   PDB; 4FCB; X-ray; 2.10 A; A/B=439-779.
DR   PDB; 4FCD; X-ray; 2.02 A; A/B=439-779.
DR   PDB; 4HEU; X-ray; 2.00 A; A/B=442-759.
DR   PDB; 4HF4; X-ray; 2.00 A; A/B=442-759.
DR   PDB; 4LKQ; X-ray; 1.62 A; A/B=439-779.
DR   PDB; 4LLJ; X-ray; 1.56 A; A/B=439-779.
DR   PDB; 4LLK; X-ray; 1.55 A; A/B=439-779.
DR   PDB; 4LLP; X-ray; 1.75 A; A/B=439-779.
DR   PDB; 4LLX; X-ray; 1.75 A; A/B=439-779.
DR   PDB; 4LM0; X-ray; 1.66 A; A/B=439-779.
DR   PDB; 4LM1; X-ray; 1.60 A; A/B=439-779.
DR   PDB; 4LM2; X-ray; 1.55 A; A/B=439-779.
DR   PDB; 4LM3; X-ray; 1.49 A; A/B=439-779.
DR   PDB; 4LM4; X-ray; 1.48 A; A/B=439-779.
DR   PDB; 4MRW; X-ray; 1.96 A; A/B=439-779.
DR   PDB; 4MRZ; X-ray; 1.58 A; A/B=439-779.
DR   PDB; 4MS0; X-ray; 1.79 A; A/B=439-779.
DR   PDB; 4MSA; X-ray; 1.62 A; A/B=439-779.
DR   PDB; 4MSC; X-ray; 2.47 A; A/B=439-779.
DR   PDB; 4MSE; X-ray; 2.81 A; A/B=439-779.
DR   PDB; 4MSH; X-ray; 2.30 A; A/B=439-779.
DR   PDB; 4MSN; X-ray; 2.30 A; A/B=439-779.
DR   PDB; 4MUW; X-ray; 2.64 A; A/B=442-779.
DR   PDB; 4MVH; X-ray; 2.50 A; A/B=442-779.
DR   PDB; 4P0N; X-ray; 2.08 A; A/B=442-779.
DR   PDB; 4P1R; X-ray; 2.24 A; A/B=442-779.
DR   PDB; 4PHW; X-ray; 2.50 A; A/B=442-779.
DR   PDB; 4TPM; X-ray; 2.77 A; A/B=442-779.
DR   PDB; 4TPP; X-ray; 2.65 A; A/B=442-779.
DR   PDB; 4WN1; X-ray; 3.13 A; A/B=439-779.
DR   PDB; 4XY2; X-ray; 2.03 A; A/B=439-779.
DR   PDB; 4YQH; X-ray; 2.31 A; A/B=439-759.
DR   PDB; 4YS7; X-ray; 2.50 A; A/B=439-759.
DR   PDB; 4ZO5; X-ray; 2.50 A; A/B=439-759.
DR   PDB; 5AXP; X-ray; 1.95 A; A/B=442-779.
DR   PDB; 5AXQ; X-ray; 1.77 A; A/B=442-779.
DR   PDB; 5B4K; X-ray; 2.90 A; A/B=442-779.
DR   PDB; 5B4L; X-ray; 2.40 A; A/B=442-779.
DR   PDB; 5C1W; X-ray; 1.70 A; A/B=439-779.
DR   PDB; 5C28; X-ray; 1.56 A; A/B=439-779.
DR   PDB; 5C29; X-ray; 2.05 A; A/B=439-779.
DR   PDB; 5C2A; X-ray; 2.00 A; A/B=439-779.
DR   PDB; 5C2E; X-ray; 2.10 A; A/B=439-779.
DR   PDB; 5C2H; X-ray; 2.09 A; A/B=439-779.
DR   PDB; 5DH4; X-ray; 2.20 A; A/B=439-779.
DR   PDB; 5DH5; X-ray; 2.00 A; A/B=439-779.
DR   PDB; 5EDE; X-ray; 2.20 A; A/C/D=447-760, B=448-760.
DR   PDB; 5EDG; X-ray; 2.30 A; A/B/C/D=447-760.
DR   PDB; 5EDH; X-ray; 2.03 A; A/B/C/D=448-760.
DR   PDB; 5EDI; X-ray; 2.20 A; A/B/C/D=442-760.
DR   PDB; 5I2R; X-ray; 2.50 A; A/B/C/D=447-763.
DR   PDB; 5K9R; X-ray; 2.70 A; A/B=448-759.
DR   PDBsum; 1LRB; -.
DR   PDBsum; 2OUN; -.
DR   PDBsum; 2OUP; -.
DR   PDBsum; 2OUQ; -.
DR   PDBsum; 2OUR; -.
DR   PDBsum; 2OUS; -.
DR   PDBsum; 2OUU; -.
DR   PDBsum; 2OUV; -.
DR   PDBsum; 2OUY; -.
DR   PDBsum; 2WEY; -.
DR   PDBsum; 2Y0J; -.
DR   PDBsum; 2ZMF; -.
DR   PDBsum; 3SN7; -.
DR   PDBsum; 3SNI; -.
DR   PDBsum; 3SNL; -.
DR   PDBsum; 3UI7; -.
DR   PDBsum; 3UUO; -.
DR   PDBsum; 3WI2; -.
DR   PDBsum; 3WS8; -.
DR   PDBsum; 3WS9; -.
DR   PDBsum; 3WYK; -.
DR   PDBsum; 3WYL; -.
DR   PDBsum; 3WYM; -.
DR   PDBsum; 4AEL; -.
DR   PDBsum; 4AJD; -.
DR   PDBsum; 4AJF; -.
DR   PDBsum; 4AJG; -.
DR   PDBsum; 4AJM; -.
DR   PDBsum; 4BBX; -.
DR   PDBsum; 4DDL; -.
DR   PDBsum; 4DFF; -.
DR   PDBsum; 4FCB; -.
DR   PDBsum; 4FCD; -.
DR   PDBsum; 4HEU; -.
DR   PDBsum; 4HF4; -.
DR   PDBsum; 4LKQ; -.
DR   PDBsum; 4LLJ; -.
DR   PDBsum; 4LLK; -.
DR   PDBsum; 4LLP; -.
DR   PDBsum; 4LLX; -.
DR   PDBsum; 4LM0; -.
DR   PDBsum; 4LM1; -.
DR   PDBsum; 4LM2; -.
DR   PDBsum; 4LM3; -.
DR   PDBsum; 4LM4; -.
DR   PDBsum; 4MRW; -.
DR   PDBsum; 4MRZ; -.
DR   PDBsum; 4MS0; -.
DR   PDBsum; 4MSA; -.
DR   PDBsum; 4MSC; -.
DR   PDBsum; 4MSE; -.
DR   PDBsum; 4MSH; -.
DR   PDBsum; 4MSN; -.
DR   PDBsum; 4MUW; -.
DR   PDBsum; 4MVH; -.
DR   PDBsum; 4P0N; -.
DR   PDBsum; 4P1R; -.
DR   PDBsum; 4PHW; -.
DR   PDBsum; 4TPM; -.
DR   PDBsum; 4TPP; -.
DR   PDBsum; 4WN1; -.
DR   PDBsum; 4XY2; -.
DR   PDBsum; 4YQH; -.
DR   PDBsum; 4YS7; -.
DR   PDBsum; 4ZO5; -.
DR   PDBsum; 5AXP; -.
DR   PDBsum; 5AXQ; -.
DR   PDBsum; 5B4K; -.
DR   PDBsum; 5B4L; -.
DR   PDBsum; 5C1W; -.
DR   PDBsum; 5C28; -.
DR   PDBsum; 5C29; -.
DR   PDBsum; 5C2A; -.
DR   PDBsum; 5C2E; -.
DR   PDBsum; 5C2H; -.
DR   PDBsum; 5DH4; -.
DR   PDBsum; 5DH5; -.
DR   PDBsum; 5EDE; -.
DR   PDBsum; 5EDG; -.
DR   PDBsum; 5EDH; -.
DR   PDBsum; 5EDI; -.
DR   PDBsum; 5I2R; -.
DR   PDBsum; 5K9R; -.
DR   ProteinModelPortal; Q9Y233; -.
DR   SMR; Q9Y233; -.
DR   BioGrid; 116057; 2.
DR   IntAct; Q9Y233; 1.
DR   MINT; MINT-1401257; -.
DR   STRING; 9606.ENSP00000438284; -.
DR   BindingDB; Q9Y233; -.
DR   ChEMBL; CHEMBL4409; -.
DR   DrugBank; DB08384; 2-({4-[4-(pyridin-4-ylmethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline.
DR   DrugBank; DB08387; 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline.
DR   DrugBank; DB08386; 2-{[4-(4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline.
DR   DrugBank; DB00201; Caffeine.
DR   DrugBank; DB00975; Dipyridamole.
DR   DrugBank; DB01113; Papaverine.
DR   DrugBank; DB08811; Tofisopam.
DR   DrugBank; DB08814; Triflusal.
DR   GuidetoPHARMACOLOGY; 1310; -.
DR   iPTMnet; Q9Y233; -.
DR   PhosphoSitePlus; Q9Y233; -.
DR   SwissPalm; Q9Y233; -.
DR   BioMuta; PDE10A; -.
DR   DMDM; 7993747; -.
DR   PaxDb; Q9Y233; -.
DR   PeptideAtlas; Q9Y233; -.
DR   PRIDE; Q9Y233; -.
DR   Ensembl; ENST00000366882; ENSP00000355847; ENSG00000112541. [Q9Y233-1]
DR   Ensembl; ENST00000539869; ENSP00000438284; ENSG00000112541. [Q9Y233-2]
DR   GeneID; 10846; -.
DR   KEGG; hsa:10846; -.
DR   UCSC; uc003quo.4; human. [Q9Y233-1]
DR   CTD; 10846; -.
DR   DisGeNET; 10846; -.
DR   GeneCards; PDE10A; -.
DR   HGNC; HGNC:8772; PDE10A.
DR   HPA; CAB045998; -.
DR   HPA; HPA047200; -.
DR   MIM; 610652; gene.
DR   MIM; 616921; phenotype.
DR   MIM; 616922; phenotype.
DR   neXtProt; NX_Q9Y233; -.
DR   OpenTargets; ENSG00000112541; -.
DR   PharmGKB; PA33120; -.
DR   eggNOG; KOG3689; Eukaryota.
DR   eggNOG; ENOG410XRI7; LUCA.
DR   GeneTree; ENSGT00760000119066; -.
DR   HOGENOM; HOG000007068; -.
DR   HOVERGEN; HBG082113; -.
DR   KO; K18438; -.
DR   OMA; CRFTMSV; -.
DR   OrthoDB; EOG091G037C; -.
DR   PhylomeDB; Q9Y233; -.
DR   TreeFam; TF316499; -.
DR   BRENDA; 3.1.4.17; 2681.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   Reactome; R-HSA-418555; G alpha (s) signalling events.
DR   SIGNOR; Q9Y233; -.
DR   UniPathway; UPA00762; UER00747.
DR   UniPathway; UPA00763; UER00748.
DR   EvolutionaryTrace; Q9Y233; -.
DR   GeneWiki; PDE10A; -.
DR   GenomeRNAi; 10846; -.
DR   PRO; PR:Q9Y233; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   Bgee; ENSG00000112541; -.
DR   CleanEx; HS_PDE10A; -.
DR   ExpressionAtlas; Q9Y233; baseline and differential.
DR   Genevisible; Q9Y233; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; IEA:Ensembl.
DR   GO; GO:0043204; C:perikaryon; IEA:Ensembl.
DR   GO; GO:0004115; F:3',5'-cyclic-AMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0047555; F:3',5'-cyclic-GMP phosphodiesterase activity; TAS:Reactome.
DR   GO; GO:0004114; F:3',5'-cyclic-nucleotide phosphodiesterase activity; TAS:ProtInc.
DR   GO; GO:0030552; F:cAMP binding; IDA:UniProtKB.
DR   GO; GO:0030553; F:cGMP binding; NAS:UniProtKB.
DR   GO; GO:0004118; F:cGMP-stimulated cyclic-nucleotide phosphodiesterase activity; IDA:UniProtKB.
DR   GO; GO:0008144; F:drug binding; IEA:Ensembl.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006198; P:cAMP catabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0046069; P:cGMP catabolic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0043949; P:regulation of cAMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0010738; P:regulation of protein kinase A signaling; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR   Gene3D; 1.10.1300.10; -; 1.
DR   Gene3D; 3.30.450.40; -; 2.
DR   InterPro; IPR003018; GAF.
DR   InterPro; IPR029016; GAF_dom-like.
DR   InterPro; IPR003607; HD/PDEase_dom.
DR   InterPro; IPR023088; PDEase.
DR   InterPro; IPR002073; PDEase_catalytic_dom.
DR   InterPro; IPR023174; PDEase_CS.
DR   Pfam; PF01590; GAF; 2.
DR   Pfam; PF00233; PDEase_I; 1.
DR   PRINTS; PR00387; PDIESTERASE1.
DR   SMART; SM00065; GAF; 2.
DR   SMART; SM00471; HDc; 1.
DR   SUPFAM; SSF55781; SSF55781; 2.
DR   PROSITE; PS00126; PDEASE_I; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing; cAMP;
KW   cAMP-binding; cGMP; cGMP-binding; Complete proteome; Cytoplasm;
KW   Disease mutation; Hydrolase; Metal-binding; Nucleotide-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat.
FT   CHAIN         1    779       cAMP and cAMP-inhibited cGMP 3',5'-cyclic
FT                                phosphodiesterase 10A.
FT                                /FTId=PRO_0000198843.
FT   DOMAIN       91    234       GAF 1.
FT   DOMAIN      266    412       GAF 2.
FT   REGION      286    287       Allosteric effector binding.
FT   REGION      330    331       Allosteric effector binding.
FT   ACT_SITE    515    515       Proton donor. {ECO:0000250}.
FT   METAL       519    519       Divalent metal cation 1.
FT   METAL       553    553       Divalent metal cation 1.
FT   METAL       554    554       Divalent metal cation 1.
FT   METAL       554    554       Divalent metal cation 2.
FT   METAL       664    664       Divalent metal cation 1.
FT   BINDING     364    364       Allosteric effector.
FT   BINDING     383    383       Allosteric effector.
FT   BINDING     515    515       Substrate.
FT   BINDING     716    716       Substrate.
FT   VAR_SEQ       1     13       MRIEERKSQHLTG -> MEDGPSNNASCFRRLTECFLSPS
FT                                (in isoform PDE10A2).
FT                                {ECO:0000303|PubMed:10393245,
FT                                ECO:0000303|PubMed:10441464}.
FT                                /FTId=VSP_004601.
FT   VARIANT      97     97       Y -> C (in IOLOD; decreased protein
FT                                abundance; dbSNP:rs778899140).
FT                                {ECO:0000269|PubMed:27058446}.
FT                                /FTId=VAR_076798.
FT   VARIANT     106    106       A -> P (in IOLOD; decreased protein
FT                                abundance).
FT                                {ECO:0000269|PubMed:27058446}.
FT                                /FTId=VAR_076799.
FT   VARIANT     290    290       F -> L (in ADSD2; no effect on basal
FT                                3',5'-cyclic-nucleotide phosphodiesterase
FT                                activity; the mutation severely disrupts
FT                                the stimulatory effect on the enzyme
FT                                activity mediated by cAMP binding).
FT                                {ECO:0000269|PubMed:27058447}.
FT                                /FTId=VAR_076800.
FT   VARIANT     303    303       L -> P.
FT                                /FTId=VAR_008797.
FT   VARIANT     324    324       F -> L (in ADSD2; no effect on basal
FT                                3',5'-cyclic-nucleotide phosphodiesterase
FT                                activity; the mutation severely disrupts
FT                                the stimulatory effect on the enzyme
FT                                activity mediated by cAMP binding).
FT                                {ECO:0000269|PubMed:27058447}.
FT                                /FTId=VAR_076801.
FT   VARIANT     706    706       R -> K (in dbSNP:rs2224252).
FT                                /FTId=VAR_047822.
FT   VARIANT     707    707       D -> N (in dbSNP:rs2860112).
FT                                /FTId=VAR_047823.
FT   MUTAGEN     554    554       D->A: Loss of activity and of zinc
FT                                binding. {ECO:0000269|PubMed:17389385}.
FT   MUTAGEN     554    554       D->N: Reduces activity 1000-fold.
FT                                {ECO:0000269|PubMed:17389385}.
FT   CONFLICT    657    657       G -> S (in Ref. 4; CAG38804).
FT                                {ECO:0000305}.
FT   HELIX       247    262       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       267    282       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      284    293       {ECO:0000244|PDB:2ZMF}.
FT   TURN        294    297       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      298    304       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      323    325       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       329    337       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      341    344       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       346    348       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       355    360       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      367    374       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      377    387       {ECO:0000244|PDB:2ZMF}.
FT   STRAND      390    392       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       395    419       {ECO:0000244|PDB:2ZMF}.
FT   HELIX       443    449       {ECO:0000244|PDB:2OUR}.
FT   HELIX       456    461       {ECO:0000244|PDB:2OUR}.
FT   STRAND      464    466       {ECO:0000244|PDB:3UI7}.
FT   HELIX       470    475       {ECO:0000244|PDB:2OUR}.
FT   HELIX       476    488       {ECO:0000244|PDB:2OUR}.
FT   TURN        490    492       {ECO:0000244|PDB:3SNI}.
FT   HELIX       495    507       {ECO:0000244|PDB:2OUR}.
FT   STRAND      513    516       {ECO:0000244|PDB:2OUR}.
FT   HELIX       517    532       {ECO:0000244|PDB:2OUR}.
FT   HELIX       533    537       {ECO:0000244|PDB:2OUR}.
FT   HELIX       540    552       {ECO:0000244|PDB:2OUR}.
FT   TURN        553    556       {ECO:0000244|PDB:2OUR}.
FT   HELIX       562    567       {ECO:0000244|PDB:2OUR}.
FT   HELIX       571    575       {ECO:0000244|PDB:2OUR}.
FT   STRAND      577    579       {ECO:0000244|PDB:2OUS}.
FT   HELIX       580    593       {ECO:0000244|PDB:2OUR}.
FT   TURN        596    598       {ECO:0000244|PDB:3SN7}.
FT   TURN        600    603       {ECO:0000244|PDB:2OUR}.
FT   HELIX       606    622       {ECO:0000244|PDB:2OUR}.
FT   HELIX       625    640       {ECO:0000244|PDB:2OUR}.
FT   STRAND      646    648       {ECO:0000244|PDB:3WI2}.
FT   HELIX       649    664       {ECO:0000244|PDB:2OUR}.
FT   HELIX       666    669       {ECO:0000244|PDB:2OUR}.
FT   HELIX       672    695       {ECO:0000244|PDB:2OUR}.
FT   HELIX       702    704       {ECO:0000244|PDB:2OUR}.
FT   HELIX       706    711       {ECO:0000244|PDB:2OUR}.
FT   HELIX       712    722       {ECO:0000244|PDB:2OUR}.
FT   HELIX       724    734       {ECO:0000244|PDB:2OUR}.
FT   HELIX       736    738       {ECO:0000244|PDB:2OUR}.
FT   HELIX       739    757       {ECO:0000244|PDB:2OUR}.
FT   HELIX       762    765       {ECO:0000244|PDB:5C28}.
SQ   SEQUENCE   779 AA;  88412 MW;  C5651BBB524A32B7 CRC64;
     MRIEERKSQH LTGLTDEKVK AYLSLHPQVL DEFVSESVSA ETVEKWLKRK NNKSEDESAP
     KEVSRYQDTN MQGVVYELNS YIEQRLDTGG DNQLLLYELS SIIKIATKAD GFALYFLGEC
     NNSLCIFTPP GIKEGKPRLI PAGPITQGTT VSAYVAKSRK TLLVEDILGD ERFPRGTGLE
     SGTRIQSVLC LPIVTAIGDL IGILELYRHW GKEAFCLSHQ EVATANLAWA SVAIHQVQVC
     RGLAKQTELN DFLLDVSKTY FDNIVAIDSL LEHIMIYAKN LVNADRCALF QVDHKNKELY
     SDLFDIGEEK EGKPVFKKTK EIRFSIEKGI AGQVARTGEV LNIPDAYADP RFNREVDLYT
     GYTTRNILCM PIVSRGSVIG VVQMVNKISG SAFSKTDENN FKMFAVFCAL ALHCANMYHR
     IRHSECIYRV TMEKLSYHSI CTSEEWQGLM QFTLPVRLCK EIELFHFDIG PFENMWPGIF
     VYMVHRSCGT SCFELEKLCR FIMSVKKNYR RVPYHNWKHA VTVAHCMYAI LQNNHTLFTD
     LERKGLLIAC LCHDLDHRGF SNSYLQKFDH PLAALYSTST MEQHHFSQTV SILQLEGHNI
     FSTLSSSEYE QVLEIIRKAI IATDLALYFG NRKQLEEMYQ TGSLNLNNQS HRDRVIGLMM
     TACDLCSVTK LWPVTKLTAN DIYAEFWAEG DEMKKLGIQP IPMMDRDKKD EVPQGQLGFY
     NAVAIPCYTT LTQILPPTEP LLKACRDNLS QWEKVIRGEE TATWISSPSV AQKAAASED
//
